Medicus Pharma Presents at Brookline Capital Markets

Medicus Pharma Ltd., a NASDAQ-listed biotech company, will present at Brookline Capital Markets. They will focus on two key developments: the Doxorubicin Microneedle Array (D-MNA) for non-invasive basal cell carcinoma treatment, and Teverelix, a GnRH antagonist for acute urinary retention and high-risk prostate cancer.

Both projects present a market potential of $8 billion. The presentation will include a company overview by CEO Raza Bokhari and updates from Ed Brennan and Faisal Mehmud, covering clinical progress and product potential.

The event will conclude with a live Q&A. The ongoing clinical trials span the United States and UAE, involving 90 participants for D-MNA and Teverelix's expansion following a UK company acquisition.